Status:
UNKNOWN
99mTc-ABH2 SPECT/CT in Breast Cancer
Lead Sponsor:
Peking Union Medical College Hospital
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
This prospective study will investigate the potential usefulness of 99mTc-ABH2 SPECT/CT in the diagnostic performance and evaluation efficacy of breast cancer.
Detailed Description
This study aims to assess the diagnostic performance of 99mTc-ABH2 SPECT/CT for the detection of HER2-positive primary breast cancer and possible metastases. Visual and semiquantitative methods will b...
Eligibility Criteria
Inclusion
- clinically suspected primary breast cancer by mammography or ultrasonography and being able to sign the written informed consent form
Exclusion
- pregnancy or lactation, impaired liver or kidney failure, and undergoing any preceding local or systemic therapies that might interfere HER2 binding
Key Trial Info
Start Date :
March 20 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 30 2024
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06194565
Start Date
March 20 2023
End Date
January 30 2024
Last Update
January 8 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China, 100730